Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

S-095035

Small molecule · Inhibitor of methionine adenosyltransferase II alpha (MAT2A)

Phase 1/2 Most advanced trial
1 Registered trials

What is S-095035?

S-095035 is an orally bioavailable inhibitor of methionine adenosyltransferase II alpha (MAT2A), the enzyme that produces S-adenosyl-L-methionine, a primary methyl donor for cellular transmethylation. It is being studied in MTAP-deleted solid tumors, which depend heavily on MAT2A activity.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
methionine adenosyltransferase II alpha (MAT2A)
Mechanism
Inhibitor of methionine adenosyltransferase II alpha (MAT2A)
Pathways
S-adenosyl-L-methionine synthesis, transmethylation, methionine salvage pathway
Therapy area
Oncology
In trials of
TNGX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06188702 Phase 1/2 MTAP-deleted Solid Tumors Active not recruiting TNGX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

MTAP-deleted Solid Tumors

Other drugs acting on MAT2A

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.